The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to ...

For present purposes, the claims of the ‘659 Patent called for a pharmaceutical combination comprising valsartan and sacubitril “administered in combination” in about a 1:1 ratio.

Because the proposed generic drug accused of infringement was a “complex” of bonded valsartan ... sacubitril, the patentee Novartis needed to urge and had successfully urged that ...

Entresto (sacubitril+valsartan) was FDA-approved in patients ... to determine whether Verquvo is superior to placebo, both in combination with other heart failure therapies, in reducing the ...

although women who are breastfeeding need modifications to their regimen because the angiotensin receptor-neprilysin inhibitor combination, sacubitril with valsartan, does not have safety data on ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The company’s earnings surpassed estimates in each of the trailing four ...

Chronic Heart Failure Market Outlook 2025-2035: The 7 major chronic heart failure market reached a value of USD 7.2 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 20.3 ...